Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DICE DICE Therapeutics (DICE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About DICE Therapeutics Stock (NASDAQ:DICE) 30 days 90 days 365 days Advanced Chart Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… Get DICE Therapeutics alerts:Sign Up Key Stats Today's Range$47.55▼$47.5550-Day Range$46.62▼$47.5552-Week Range$15.08▼$47.90VolumeN/AAverage Volume1.03 million shsMarket Capitalization$2.27 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewDICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.Read More… top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… Receive DICE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DICE Stock News HeadlinesWe tried Factor’s prepared meal delivery service for over three years: Full reviewOctober 12, 2024 | msn.comEverything You Need To Know About Zelda: Echoes Of WisdomSeptember 26, 2024 | msn.comThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. October 31, 2024 | Porter & Company (Ad)Steven Schumacher joins Stoke City list of doom as ruthless Jon Walters takes responsibilitySeptember 16, 2024 | msn.comEli Lilly and Company (LLY): Jim Cramer's Go-To Stock For SuccessAugust 31, 2024 | msn.comLilly beefs up bowel disease drug portfolio with $3.2 billion Morphic dealAugust 8, 2024 | msn.comIs Eli Lilly Stock Headed Toward $1300 Levels?July 26, 2024 | forbes.com"It's just a disgrace": Port Richmond residents demand city fix multiple craters on Aramingo AvenueJuly 25, 2024 | yahoo.comSee More Headlines DICE Stock Analysis - Frequently Asked Questions How were DICE Therapeutics' earnings last quarter? DICE Therapeutics, Inc. (NASDAQ:DICE) announced its quarterly earnings data on Friday, November, 12th. The company reported ($2.30) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by $1.77. When did DICE Therapeutics IPO? DICE Therapeutics (DICE) raised $160 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 10,000,000 shares at $15.00-$17.00 per share. What other stocks do shareholders of DICE Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that DICE Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX), Honeywell International (HON), HubSpot (HUBS), Walt Disney (DIS) and Bank of America (BAC). Company Calendar Last Earnings11/12/2021Today10/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:DICE CUSIPN/A CIK1645569 Webwww.dicemolecules.com Phone650-566-1420FaxN/AEmployees71Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-22.01% Return on Assets-20.79% Debt Debt-to-Equity RatioN/A Current Ratio25.88 Quick Ratio32.44 Sales & Book Value Annual Sales$1.13 million Price / Sales2,008.50 Cash FlowN/A Price / Cash FlowN/A Book Value$10.86 per share Price / Book4.38Miscellaneous Outstanding Shares47,731,000Free Float45,392,000Market Cap$2.27 billion OptionableNot Optionable Beta1.03 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:DICE) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DICE Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DICE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.